Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | British Journal of Haematology |
| Vol/bind | 196 |
| Udgave nummer | 2 |
| Sider (fra-til) | 437-440 |
| Antal sider | 4 |
| ISSN | 0007-1048 |
| DOI |
|
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
We thank all the patients and the participating centres for their contribution. We thank Gilead for contribution with research grant and supply of study drug idelalisib.
ID: 346779530